How do you decide on initial and sequential anti-CD20 therapy for patients with multiple sclerosis given the availability of rituximab, ocrelizumab, ublituximab, and ofatumumab?  

In my practice, I generally discuss the B cell depleter drug class with patients, as these drugs have similar clinical profiles. I do not have a particular preference for sequencing one anti-CD20 drug over another. Treatment decisions are primarily driven by practical differences for patients, such ...

Monoclonal antibodies for MS include natalizumab, ocrelizumab, rituximab, ofatumumab, alemtuzumab, and ublituximab. These DMTs are highly efficacious for reducing the relapse rate in patients with MS, but serious safety issues, including infections, are possible adverse effects of several of these m...